A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

NCT04328844 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Non-Hodgkin Lymphoma, Adult
NSCLC
Myelofibrosis
Uveal Melanoma

Interventions

DRUG: IOA-244
DRUG: Avelumab Injection
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Ruxolitinib

Sponsor

iOnctura